NEW YORK (GenomeWeb News) – Genetic testing technology company DxTerity Diagnostics said today that it has acquired the intellectual property rights to several blood-based cancer diagnostic tests from SourceMDx.
The IP covers gene expression assays for early diagnosis of breast and lung cancer and a test for determining survival and response to therapy for melanoma patients. They are covered by a portfolio of more than 30 US and international patent filings.
The Los Angeles-based firms said that it has begun migrating these tests to function on its Non-Enzymatic Amplification Technology (NEAT) platform, which is designed to make genetic testing easier and cheaper.
The NEAT technology eliminates the need for sample purification and enzymatic amplification, and it is based on technology DxTerity has licensed from Stanford University, where it was developed.
"The NEAT platform is perfect for blood-based genomic testing since it enables the simultaneous direct-from-sample measurement of up to 40 gene targets," DxTerity CEO Bob Terbrueggen said in a statement.
Financial terms of the agreement were not disclosed.